Subcutaneous ICD therapy in patients with monomorphic ventricular tachycardia: Arrhythmia recurrence, shock rate, and management strategies
Heart Rhythm · 2026
DOI: 10.1016/j.hrthm.2026.05.034 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Heart Rhythm, 2026. Verfasst von Giovanni Luca Botto und 17 weiteren Autor:innen. Beteiligte Einrichtung: ASST Rhodense, Rho and Garbagnate M.se Hospitals, Milan, Italy. Electronic address: gluca.botto@gmail.com. Hauptthemen laut MEDLINE: Death, Sudden, Cardiac, Defibrillators, Implantable, Electric Countershock, Tachycardia, Ventricular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) is recommended for patients at risk of sudden cardiac death who do not require pacing or antitachycardia pacing (ATP). However, patients with a history of monomorphic ventricular tachycardia (MVT), which is often amenable to ATP, are underrepresented in clinical studies dealing with S-ICD. OBJECTIVE: This study aimed to evaluate outcomes of S-ICD therapy in patients with previous MVT and describe subsequent management strategies in clinical practice. METHODS: From 2164 consecutive de novo S-ICD implantations, we identified 210 patients (10%) with a history of sustained MVT. Clinical characteristics, procedural data, and outcomes were analyzed. The endpoints of the study included the rates of sustained MVT and S-ICD shocks for all ventricular arrhythmias. RESULTS: During a median follow-up of 43 months (interquartile range 21-70), 21 patients (10%) experienced 66 MVT episodes (60 isolated, 6 storms) and a total of 98 ventricular arrhythmic episodes, all successfully terminated by shocks. The annualized rate of MVT was 2.8%/y, and the rate of appropriate shocks was 4.9%/y. First-shock efficacy was 93% for both MVT and polymorphic ventricular tachycardia/ventricular fibrillation. Approximately half of patients with recurrent MVT underwent ablation, with high procedural success. No patient required S-ICD explantation or conversion to a transvenous implantable cardioverter-defibrillator for ATP delivery. The complication rate was 2.3%/y and the inappropriate shock rate 2.8%/y. CONCLUSION: In patients with previous MVT, the S-ICD provided safe and effective protection against ventricular arrhythmias. Ablation was the preferred management strategy, and no patients required conversion to a transvenous device. These findings support the use of the S-ICD as a viable option in this patient population. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov/ identifier: NCT02275637.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ASST Rhodense, Rho and Garbagnate M.se Hospitals, Milan, Italy. Electronic address: gluca.botto@gmail.com.
- Department of Cardiac, Thoracic Vascular Sciences and Public Health University of Padova, Padova, Italy.
- Electrophysiology Unit, Careggi University Hospital, Florence, Italy.
- Second Cardiology Division, Cardio-Thoracic and Vascular Department, University Hospital of Pisa, Pisa, Italy.
- Center of Excellence in Cardiovascular Sciences, Ospedale Isola Tiberina - Gemelli Isola, Rome, Italy.
- Institute of Cardiology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Zitieren
APA
Botto, G. L., Migliore, F., Pieragnoli, P., Viani, S., Bisignani, A., Ziacchi, M., Silvetti, M. S., Nigro, G., Bianchi, V., Mariani, M. V., Savarese, G., Pittorru, R., Bambagioni, G., Lovecchio, M., Valsecchi, S., Biffi, M., Casale, M. C., & “S-ICD Rhythm Detect” investigators (2026). Subcutaneous ICD therapy in patients with monomorphic ventricular tachycardia: Arrhythmia recurrence, shock rate, and management strategies. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2026.05.034
Vancouver
Botto GL, Migliore F, Pieragnoli P, Viani S, Bisignani A, Ziacchi M, et al. Subcutaneous ICD therapy in patients with monomorphic ventricular tachycardia: Arrhythmia recurrence, shock rate, and management strategies. Heart Rhythm. 2026. doi:10.1016/j.hrthm.2026.05.034
BibTeX
@article{Botto2026,
author = {Botto, Giovanni Luca and Migliore, Federico and Pieragnoli, Paolo and Viani, Stefano and Bisignani, Antonio and Ziacchi, Matteo and Silvetti, Massimo Stefano and Nigro, Gerardo and Bianchi, Valter and Mariani, Marco Valerio and Savarese, Gianluca and Pittorru, Raimondo and Bambagioni, Gabriele and Lovecchio, Mariolina and Valsecchi, Sergio and Biffi, Mauro and Casale, Maria Carla and “S-ICD Rhythm Detect” investigators, “S-ICD Rhythm Detect” investigators},
title = {Subcutaneous ICD therapy in patients with monomorphic ventricular tachycardia: Arrhythmia recurrence, shock rate, and management strategies},
journal = {Heart Rhythm},
year = {2026},
doi = {10.1016/j.hrthm.2026.05.034}
}
EUVIMED